Paul Waako | |
---|---|
Born | Mukuta Village, Mayuge District, Uganda | 20 February 1967
Alma mater | Makerere University (Bachelor of Medicine and Bachelor of Surgery) (Master of Science in Pharmacology) University of Cape Town (Doctor of Philosophy in Clinical Pharmacology) Uganda Management Institute (Postgraduate Diploma in Management) |
Occupation | Vice Chancellor of Busitema University |
Known for | Professional competence |
Title | Vice Chancellor of Busitema University |
Professor Paul Waako (born 20 February 1967), is a Ugandan pharmacologist, academic and academic administrator, who serves as the Vice Chancellor of Busitema University, a public university in the Eastern Region of Uganda, since 1 May 2019. [1]
Waako was born on 20 February 1967 at Mukuta Village, in Mayuge District, in the Eastern Region of Uganda. After attending local primary and secondary schools, he was admitted to Makerere University School of Medicine, the oldest medical school in East Africa. [1]
He holds a Bachelor of Medicine and Bachelor of Surgery degree and a Master of Science degree in Pharmacology, both awarded by Makerere University, in Uganda. His Doctor of Philosophy in Clinical Pharmacology was obtained from the University of Cape Town, in South Africa. He also holds a Postgraduate Diploma in Management, obtained from the Uganda Management Institute, in Kampala. [1]
For a period of ten years, he chaired the Department of Pharmacology and Therapeutics at Makerere University College of Health Sciences. He was then appointed Dean of Busitema University Faculty of Health Sciences, serving in that capacity from 2013 until 2019. [1]
As Vice Chancellor at Busitema University, he succeeded Professor Mary Okwakol, the founding Vice Chancellor, whose term of office ended on 30 April 2019. [2]
Professor Waako is married to Engineer Ziria Tibalwa Waako, an electrical engineer, who serves as the chief executive officer of Uganda's Electricity Regulatory Authority, since November 2016. Together, they are parents to five children. [3]
He has published extensively in the areas of traditional medicines, drug discovery and development, rational use of medicines, and medicine supply systems. He has over 50 publications in peer reviewed Journals to his name. He is a Senior Research Fellow at Queen Mary University of London. He is also a Fellow of the Uganda National Academy of Sciences. [1] [2] [3] Some of the publications include; Prevalence and factors associated with traditional herbal medicine use among patients on highly active antiretroviral therapy in Uganda. The study found that prevalence of THM use among participants on HAART was high. [4] Measuring adherence to antiretroviral treatment in resource-poor settings: The feasibility of collecting routine data for key indicators. The study evaluated the feasibility of collecting routine data to standardize adherence measurement using a draft set of indicators. [5] Traditional treatment of malaria in Mbarara District, western Uganda. [6] East African medicinal plants as a source of lead compounds for the development of new antimalarial drugs. [7] A strategy to improve skills in pharmaceutical supply management in East Africa: the regional technical resource collaboration for pharmaceutical management. The study established that the ability of trained institutions to mobilize their own resources for skills-building activities is crucial for the success and sustainability of these programmes. [8] Existing capacity to manage pharmaceuticals and related commodities in East Africa: an assessment with specific reference to antiretroviral therapy. Among others the study established that there is inadequate capacity for managing medicines and related commodities in East Africa. [9] A comparison of prescribing practices between public and private sector physicians in Uganda. [10] A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. [11] Knowledge on plants used traditionally in the treatment of tuberculosis in Uganda. This study established that plant based therapies for treating TB were identified. [12] Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. The study concluded that efavirenz related neuropsychiatric symptoms are common among Ugandan HIV patients receiving ART. [13] The prevalence and severity of mental illnesses handled by traditional healers in two districts in Uganda. [14] The anti-mycobacterial activity of Lantana camara a plant traditionally used to treat symptoms of tuberculosis in South-western Uganda. [15] Factors predicting home storage of medicines in Northern Uganda. The study established that self-medication is common among individuals in households which keep drugs. [16] Psychological distress and associated factors among the attendees of traditional healing practices in Jinja and Iganga districts, Eastern Uganda: a cross-sectional study. The study provided evidence that a substantial proportion of attendees of traditional healing practices suffer from psychological distress. [17] Patterns and Predictors of Self-Medication in Northern Uganda. [18] The in vitro and in vivo antimalarial activity of Cardiospermum halicacabum L. and Momordica foetida Schumch. Et Thonn. [19] Medicinal plants used by traditional medicine practitioners for the treatment of HIV/AIDS and related conditions in Uganda. The study identified numerous medicinal plants for treatment of HIV/AIDS patients were identified in the four districts. [20]
Tenofovir disoproxil, sold under the brand name Viread among others, is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention of HIV/AIDS among those at high risk before exposure, and after a needlestick injury or other potential exposure. It is sold both by itself and together in combinations such as emtricitabine/tenofovir, efavirenz/emtricitabine/tenofovir, and elvitegravir/cobicistat/emtricitabine/tenofovir. It does not cure HIV/AIDS or hepatitis B. It is available by mouth as a tablet or powder.
Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.
HIV/AIDS has been a public health concern for Latin America due to a remaining prevalence of the disease. In 2018 an estimated 2.2 million people had HIV in Latin America and the Caribbean, making the HIV prevalence rate approximately 0.4% in Latin America.
Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is sold both by itself and in combination as efavirenz/emtricitabine/tenofovir. It is taken by mouth.
Cytochrome P450 2B6 is an enzyme that in humans is encoded by the CYP2B6 gene. CYP2B6 is a member of the cytochrome P450 group of enzymes. Along with CYP2A6, it is involved with metabolizing nicotine, along with many other substances.
HIV/AIDS in Eswatini was first reported in 1986 but has since reached epidemic proportions. As of 2016, Eswatini had the highest prevalence of HIV among adults aged 15 to 49 in the world (27.2%).
HIV and AIDS is a major public health issue in Zimbabwe. The country is reported to hold one of the largest recorded numbers of cases in Sub-Saharan Africa. According to reports, the virus has been present in the country since roughly 40 years ago. However, evidence suggests that the spread of the virus may have occurred earlier. In recent years, the government has agreed to take action and implement treatment target strategies in order to address the prevalence of cases in the epidemic. Notable progress has been made as increasingly more individuals are being made aware of their HIV/AIDS status, receiving treatment, and reporting high rates of viral suppression. As a result of this, country progress reports show that the epidemic is on the decline and is beginning to reach a plateau. International organizations and the national government have connected this impact to the result of increased condom usage in the population, a reduced number of sexual partners, as well as an increased knowledge and support system through successful implementation of treatment strategies by the government. Vulnerable populations disproportionately impacted by HIV/AIDS in Zimbabwe include women and children, sex workers, and the LGBTQ+ population.
HIV disease–related drug reaction is an adverse drug reaction caused by drugs used for the treatment of HIV/AIDS.
Traditional African medicine is a range of traditional medicine disciplines involving indigenous herbalism and African spirituality, typically including diviners, midwives, and herbalists. Practitioners of traditional African medicine claim, largely without evidence, to be able to cure a variety of diverse conditions including cancer, psychiatric disorders, high blood pressure, cholera, most venereal diseases, epilepsy, asthma, eczema, fever, anxiety, depression, benign prostatic hyperplasia, urinary tract infections, gout, and healing of wounds and burns and Ebola.
Celestino Obua is a Ugandan physician, pharmacologist, academic and academic administrator. He is the current Vice Chancellor of Mbarara University of Science and Technology. He assumed that position on Friday, 24 October 2014. Prior to that, he served as the Deputy Principal of Makerere University College of Health Sciences.
Harriet Mayanja-Kizza is a Ugandan physician, researcher, and academic administrator. She is the former Dean of Makerere University School of Medicine, the oldest medical school in East Africa, established in 1924.
Elioda Tumwesigye is a Ugandan politician, physician, and epidemiologist who has served as minister of science, technology and innovation in the cabinet of Uganda since June 2016. From March 2015 until June 2016, he served as the minister of health.
Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.
Moses R Kamya, is a Ugandan physician, academic, researcher and academic administrator, who serves as Professor and Chair of the Department Medicine, Makerere University School of Medicine, a component of Makerere University College of Health Sciences.
Rhoda Wanyenze is a physician, public health consultant, academic and medical administrator, who serves as the Dean of Makerere University School of Public Health, a component school of Makerere University College of Health Sciences, which is part of Makerere University, Uganda's oldest and largest public university.
Elizabeth Anne Bukusi FAAS is a research professor working within the field of obstetrics and gynaecology, and global health. Bukusi's main areas of research focus around sexually transmitted infections, women's health, reproductive health, and HIV care, prevention and treatment. Bukusi is the Chief Research Officer at the Kenya Medical Research Institute (KEMRI) and led a "landmark" study on the use of PrEP in Kenya.
Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. As of 2019, it is listed by the World Health Organization (WHO) as the first line treatment for adults, with tenofovir/lamivudine/efavirenz as an alternative. It is taken by mouth.
Andrew Ddungu Kambugu is a Ugandan physician who serves as The Sande-McKinnell Executive Director at Uganda Infectious Disease Institute and a Honorary Senior lecturer at Makerere University College of Sciences. He is also an Adjunct Associate Professor at the University of Minnesota. In July 2020, he was appointed to the United Nations 2021 Food System Scientific Group.
Damalie Nakanjako, is a Ugandan specialist physician, internist, immunologist, infectious diseases consultant, academic and researcher, who serves as the Principal and Professor of Medicine at Makerere University College of Health Sciences. Immediately prior to her present position, she served as Dean of Makerere University School of Medicine, from 2019 until 17 February 2021.
Charles Williams Flexner is an American physician, clinical pharmaceutical scientist, academic, author and researcher. He is a Professor of Medicine at the Johns Hopkins University School of Medicine.
{{cite journal}}
: CS1 maint: DOI inactive as of November 2024 (link){{cite journal}}
: CS1 maint: DOI inactive as of November 2024 (link)